XR 5944

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 341465

CAS#: 343247-32-5

Description: XR 5944 is a potent DNA binding agent which stabilizes topoisomerase-dependent cleavage, thereby demonstrating exceptional efficacy against a number of murine and human tumor models.


Chemical Structure

img
XR 5944
CAS# 343247-32-5

Theoretical Analysis

MedKoo Cat#: 341465
Name: XR 5944
CAS#: 343247-32-5
Chemical Formula: C34H34N8O2
Exact Mass: 586.28
Molecular Weight: 586.700
Elemental Analysis: C, 69.61; H, 5.84; N, 19.10; O, 5.45

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Synonym: XR 5944; XR-5944; XR5944 ; MLN 944; MLN-944; MLN944

IUPAC/Chemical Name: N,N'-(1,2-Ethanediylbis(imino-2,1-ethanediyl))bis(9-methyl-1-phenazinecarboxamide)

InChi Key: SFOADSRLCHRTKT-UHFFFAOYSA-N

InChi Code: InChI=1S/C34H34N8O2/c1-21-7-3-11-25-29(21)41-31-23(9-5-13-27(31)39-25)33(43)37-19-17-35-15-16-36-18-20-38-34(44)24-10-6-14-28-32(24)42-30-22(2)8-4-12-26(30)40-28/h3-14,35-36H,15-20H2,1-2H3,(H,37,43)(H,38,44)

SMILES Code: O=C(C1=CC=CC2=NC3=CC=CC(C)=C3N=C21)NCCNCCNCCNC(C4=CC=CC5=NC6=CC=CC(C)=C6N=C54)=O

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 586.70 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Lin C, Yang D. DNA Recognition by a Novel Bis-Intercalator, Potent Anticancer Drug XR5944. Curr Top Med Chem. 2015;15(14):1385-97. Review. PubMed PMID: 25866279; PubMed Central PMCID: PMC4772870.

2: Lin C, Mathad RI, Zhang Z, Sidell N, Yang D. Solution structure of a 2:1 complex of anticancer drug XR5944 with TFF1 estrogen response element: insights into DNA recognition by a bis-intercalator. Nucleic Acids Res. 2014 May;42(9):6012-24. doi: 10.1093/nar/gku219. Epub 2014 Apr 7. PubMed PMID: 24711371; PubMed Central PMCID: PMC4027214.

3: Moorthy NS, Pratheepa V, Ramos MJ, Vasconcelos V, Fernandes PA. Fused aryl-phenazines: scaffold for the development of bioactive molecules. Curr Drug Targets. 2014;15(7):681-8. Review. PubMed PMID: 24499398.

4: Sidell N, Mathad RI, Shu FJ, Zhang Z, Kallen CB, Yang D. Intercalation of XR5944 with the estrogen response element is modulated by the tri-nucleotide spacer sequence between half-sites. J Steroid Biochem Mol Biol. 2011 Apr;124(3-5):121-7. doi: 10.1016/j.jsbmb.2011.02.003. Epub 2011 Feb 17. PubMed PMID: 21333738; PubMed Central PMCID: PMC3072055.

5: Wolf SJ, Wakelin LP, He Z, Stewart BW, Catchpoole DR. In vitro assessment of novel transcription inhibitors and topoisomerase poisons in rhabdomyosarcoma cell lines. Cancer Chemother Pharmacol. 2009 Nov;64(6):1059-69. doi: 10.1007/s00280-009-0962-4. Epub 2009 Mar 10. PubMed PMID: 19277661.

6: Jobson AG, Willmore E, Tilby MJ, Mistry P, Charlton P, Austin CA. Effect of phenazine compounds XR11576 and XR5944 on DNA topoisomerases. Cancer Chemother Pharmacol. 2009 Apr;63(5):889-901. doi: 10.1007/s00280-008-0812-9. Epub 2008 Aug 5. PubMed PMID: 18679685.

7: Verborg W, Thomas H, Bissett D, Waterfall J, Steiner J, Cooper M, Rankin EM. First-into-man phase I and pharmacokinetic study of XR5944.14, a novel agent with a unique mechanism of action. Br J Cancer. 2007 Oct 8;97(7):844-50. Epub 2007 Sep 11. PubMed PMID: 17848959; PubMed Central PMCID: PMC2360398.

8: Punchihewa C, De Alba A, Sidell N, Yang D. XR5944: A potent inhibitor of estrogen receptors. Mol Cancer Ther. 2007 Jan;6(1):213-9. Epub 2007 Jan 11. PubMed PMID: 17218634.

9: Lewis LJ, Mistry P, Charlton PA, Thomas H, Coley HM. Mode of action of the novel phenazine anticancer agents XR11576 and XR5944. Anticancer Drugs. 2007 Feb;18(2):139-48. PubMed PMID: 17159600.

10: Harris SM, Scott JA, Brown JL, Charlton PA, Mistry P. Preclinical anti-tumor activity of XR5944 in combination with carboplatin or doxorubicin in non-small-cell lung carcinoma. Anticancer Drugs. 2005 Oct;16(9):945-51. PubMed PMID: 16162971.

11: Harris SM, Mistry P, Freathy C, Brown JL, Charlton PA. Antitumour activity of XR5944 in vitro and in vivo in combination with 5-fluorouracil and irinotecan in colon cancer cell lines. Br J Cancer. 2005 Feb 28;92(4):722-8. PubMed PMID: 15700035; PubMed Central PMCID: PMC2361868.

12: Di Nicolantonio F, Knight LA, Whitehouse PA, Mercer SJ, Sharma S, Charlton PA, Norris D, Cree IA. The ex vivo characterization of XR5944 (MLN944) against a panel of human clinical tumor samples. Mol Cancer Ther. 2004 Dec;3(12):1631-7. PubMed PMID: 15634657.

13: Bayes M, Rabasseda X, Prous JR. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2004 Jul-Aug;26(6):473-503. PubMed PMID: 15349141.

14: Sappal DS, McClendon AK, Fleming JA, Thoroddsen V, Connolly K, Reimer C, Blackman RK, Bulawa CE, Osheroff N, Charlton P, Rudolph-Owen LA. Biological characterization of MLN944: a potent DNA binding agent. Mol Cancer Ther. 2004 Jan;3(1):47-58. PubMed PMID: 14749475.

15: Stewart AJ, Mistry P, Dangerfield W, Bootle D, Baker M, Kofler B, Okiji S, Baguley BC, Denny WA, Charlton PA. Antitumor activity of XR5944, a novel and potent topoisomerase poison. Anticancer Drugs. 2001 Apr;12(4):359-67. PubMed PMID: 11335793.